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Within the Predict-IV FP7 project a strategy for measurement of in vitro biokinetics was developed, 28 requiring the characterization of the cellular model used, especially regarding biotransformation, which 29 frequently depends on cytochrome P450 (CYP) activity. The extrahepatic in situ CYP-mediated metabo- 30 lism is especially relevant in target organ toxicity. In this study, the constitutive mRNA levels and protein 31 localization of different CYP isoforms were investigated in 3D aggregating brain cell cultures. CYP1A1, 32 CYP2B1/B2, CYP2D2/4, CYP2E1 and CYP3A were expressed; CYP1A1 and 2B1 represented almost 80% 33 of the total mRNA content. Double-immunolabeling revealed their presence in astrocytes, in neurons, 34 and to a minor extent in oligodendrocytes, confirming the cell-specific localization of CYPs in the brain. 35 These results together with the recently reported formation of an amiodarone metabolite following 36 repeated exposure suggest that this cell culture system possesses some metabolic potential, most likely 37 contributing to its high performance in neurotoxicological studies and support the use of this model in 38 studying brain neurotoxicity involving mechanisms of toxication/detoxication. The cytochrome P450 (CYP) superfamily is one of the most 46 important groups of enzymes involved in the biotransformation 47 of a large number of endogenous and exogenous compounds, 48 including toxic substances, drugs and environmental chemicals. 49 Although the liver is the primary organ responsible for 50 CYP-mediated metabolism, the relevance of extrahepatic CYP-51 mediated metabolism is widely recognized, especially regarding 52 in situ metabolism in target organ toxicity (Pavek and Dvorak, 53 2008; Ravindranath and Strobel, 2013; Rieder et al., 1998) . 54 Neurotoxicity is one of the most relevant toxicological end-points, 55 due to the crucial role played by the central nervous system (CNS) 56 in the organism functionality. 57 In the CNS CYPs have been identified as functional enzymes, 58 and are known to metabolize in situ a variety of compounds includ- The expression of CYPs in the whole brain is reported to occur at 71 only 1% of the levels found in the liver, therefore it is unlikely that 72 brain CYPs contribute to overall clearance of any xenobiotic.
However, since CYPs can be highly expressed in specific cells or 74 brain regions, the metabolism of drugs crossing the blood-brain 75 barrier can be of relevance and responsible of specific effects 76 locally within the brain Tyndale, 2002, 2004 (Fletcher, 1978 and to some extent also with MBP ( Fig. 2A) , indicating CYP1A1 370 expression in neurons and astrocytes and to some extent also in 371 oligodendrocytes.
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CYP2D4 labeling had primarily a cell-body and cellular process 373 distribution (Fig. 2B) . Some perinuclear and somal CYP2D4 labeling 374 co-localized with NF, whereas somal and cell process CYP2D4 (Fig. 2C, inset) . CYP2E1-GFAP co-localization appeared pri-382 marily in the cell body (Fig. 2C, insets) . CYP2E1 co-localization 383 signal with MBP was weak (Fig. 2C) , suggesting primarily neuronal 384 and astroglial localization of CYP2E1. Hoechst; co-localization could be detected to some extent with 388 both MAP2 and GFAP (Fig. 2D, insets around the nuclei (Fig. 2E and inset) . Little CYP3A co-localization 393 was found with NF and MBP, whereas GFAP co-localized to a 394 greater extent (Fig. 2E, insets) , indicating that CYP3A expression 395 is mainly astrocytic. (Fig. 4, lower panel) . 447 Again, limited to batch I, a biologically relevant induction after 448 24-and 48 h nicotine treatment was also observed (Fig. 4) , with 449 up to 2.5-fold increased mRNA expression as compared to controls. (Fig. 4) . In the present study, the quantification of CYP1A1 and CYP2B1 
